Search

Your search keyword '"Haass, Markus"' showing total 401 results
Start Over Author "Haass, Markus"
401 results on '"Haass, Markus"'

2. Position paper on the importance of psychosocial factors in cardiology: Update 2013

Author

Ladwig, Karl-Heinz, Lederbogen, Florian, Albus, Christian, Angermann, Christiane, Borggrefe, Martin, Fischer, Denise, Fritzsche, Kurt, Haass, Markus, Jordan, Jochen, Jünger, Jana, Kindermann, Ingrid, Köllner, Volker, Kuhn, Bernhard, Scherer, Martin, Seyfarth, Melchior, Völler, Heinz, Waller, Christiane, and Herrmann-Lingen, Christoph

Subjects
depression, anxiety, post-traumatic stress disorder, psychotherapy, psychopharmacology, Medicine
Abstract

[english] Background: The rapid progress of psychosomatic research in cardiology and also the increasing impact of psychosocial issues in the clinical daily routine have prompted the Clinical Commission of the German Heart Society (DGK) to agree to an update of the first state of the art paper on this issue which was originally released in 2008.Methods: The circle of experts was increased, general aspects were implemented and the state of the art was updated. Particular emphasis was dedicated to coronary heart diseases (CHD), heart rhythm diseases and heart failure because to date the evidence-based clinical knowledge is most advanced in these particular areas. Differences between men and women and over the life span were considered in the recommendations as were influences of cognitive capability and the interactive and synergistic impact of classical somatic risk factors on the affective comorbidity in heart disease patients.Results: A IA recommendation (recommendation grade I and evidence grade A) was given for the need to consider psychosocial risk factors in the estimation of coronary risks as etiological and prognostic risk factors. Furthermore, for the recommendation to routinely integrate psychosocial patient management into the care of heart surgery patients because in these patients, comorbid affective disorders (e.g. depression, anxiety and post-traumatic stress disorder) are highly prevalent and often have a malignant prognosis. A IB recommendation was given for the treatment of psychosocial risk factors aiming to prevent the onset of CHD, particularly if the psychosocial risk factor is harmful in itself (e.g. depression) or constrains the treatment of the somatic risk factors. Patients with acute and chronic CHD should be offered anti-depressive medication if these patients suffer from medium to severe states of depression and in this case medication with selective reuptake inhibitors should be given. In the long-term course of treatment with implanted cardioverter defibrillators (ICDs) a subjective health technology assessment is warranted. In particular, the likelihood of affective comorbidities and the onset of psychological crises should be carefully considered.Conclusions: The present state of the art paper presents an update of current empirical evidence in psychocardiology. The paper provides evidence-based recommendations for the integration of psychosocial factors into cardiological practice and highlights areas of high priority. The evidence for estimating the efficiency for psychotherapeutic and psychopharmacological interventions has increased substantially since the first release of the policy document but is, however, still weak. There remains an urgent need to establish curricula for physician competence in psychodiagnosis, communication and referral to ensure that current psychocardiac knowledge is translated into the daily routine.

Published
2014
Full Text
View/download PDF

3. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study

Author

Sadlonova, Monika, Salzmann, Stefan, Senges, Jochen, Celano, Christopher M., Huffman, Jeff C., Borggrefe, Martin, Akin, Ibrahim, Thomas, Dierk, Schwarzbach, Christopher Jan, Kleemann, Thomas, Schneider, Steffen, Hochadel, Matthias, Süselbeck, Tim, Schwacke, Harald, Alonso, Angelika, Haass, Markus, Ladwig, Karl-Heinz, and Herrmann-Lingen, Christoph

Published
2024
Full Text
View/download PDF

10. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Author

Packer, Milton, Butler, Javed, Zannad, Faiez, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Schnaidt, Sven, Zeller, Cordula, Schnee, Janet M., and Anker, Stefan D.

Published
2021
Full Text
View/download PDF

11. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study

Author

Sadlonova, Monika, primary, Salzmann, Stefan, additional, Senges, Jochen, additional, Celano, Christopher M., additional, Huffman, Jeff C., additional, Borggrefe, Martin, additional, Akin, Ibrahim, additional, Thomas, Dierk, additional, Schwarzbach, Christopher Jan, additional, Kleemann, Thomas, additional, Schneider, Steffen, additional, Hochadel, Matthias, additional, Süselbeck, Tim, additional, Schwacke, Harald, additional, Alonso, Angelika, additional, Haass, Markus, additional, Ladwig, Karl-Heinz, additional, and Herrmann-Lingen, Christoph, additional

Published
2023
Full Text
View/download PDF

13. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Author

Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Schnaidt, Sven, and Zannad, Faiez

Published
2021
Full Text
View/download PDF

14. Predictors of persistent symptoms after mRNA SARS-CoV-2 vaccine-related myocarditis (myovacc registry)

Author

Schroth, Daniel, primary, Garg, Ria, additional, Bocova, Xhoi, additional, Hansmann, Jochen, additional, Haass, Markus, additional, Yan, Andrew, additional, Fernando, Carlos, additional, Chacko, Binita, additional, Oikonomou, Anastasia, additional, White, James, additional, Alhussein, Muhammad Mustafa, additional, Giusca, Sorin, additional, Ochs, Andreas, additional, Korosoglou, Grigorios, additional, André, Florian, additional, Friedrich, Matthias G., additional, and Ochs, Marco, additional

Published
2023
Full Text
View/download PDF

16. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)

Author

Carson, Peter E., Anand, Inder S., Win, Sithu, Rector, Thomas, Haass, Markus, Lopez-Sendon, Jose, Miller, Alan, Teerlink, John R., White, Michel, McKelvie, Robert S., Komajda, Michel, Zile, Michael R., McMurray, John J., and Massie, Barry

Published
2015
Full Text
View/download PDF

17. Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling

Author

Lehmann, Lorenz H., Rostosky, Julia S., Buss, Sebastian J., Kreusser, Michael M., Krebs, Jutta, Mier, Walter, Enseleit, Frank, Spiger, Katharina, Hardt, Stefan E., Wieland, Thomas, Haass, Markus, Lüscher, Thomas F., Schneider, Michael D., Parlato, Rosanna, Gröne, Hermann-Josef, Haberkorn, Uwe, Yanagisawa, Masashi, Katus, Hugo A., and Backs, Johannes

Published
2014

19. Cardiac myocytes

Author

Haunstetter, Armin, Haass, Markus, Izumo, Seigo, Schunkert, Heribert, editor, and Riegger, G. A. J., editor

Published
2000
Full Text
View/download PDF

21. Symptom Severity and Health-Related Quality of Life in Patients with Atrial Fibrillation: Findings from the Observational ARENA Study

Author

Sadlonova, Monika, primary, Senges, Jochen, additional, Nagel, Jonas, additional, Celano, Christopher, additional, Klasen-Max, Caroline, additional, Borggrefe, Martin, additional, Akin, Ibrahim, additional, Thomas, Dierk, additional, Schwarzbach, Christopher Jan, additional, Kleeman, Thomas, additional, Schneider, Steffen, additional, Hochadel, Matthias, additional, Süselbeck, Tim, additional, Schwacke, Harald, additional, Alonso, Angelika, additional, Haass, Markus, additional, Ladwig, Karl-Heinz, additional, and Herrmann-Lingen, Christoph, additional

Published
2022
Full Text
View/download PDF

22. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

Author

O'Connor, Christopher M., Miller, Alan B., Blair, John E.A., Konstam, Marvin A., Wedge, Patricia, Bahit, Maria C., Carson, Peter, Haass, Markus, Hauptman, Paul J., Metra, Marco, Oren, Ron M., Patten, Richard, Piña, Ileana, Roth, Sherryn, Sackner-Bernstein, Jonathan D., Traver, Brian, Cook, Thomas, and Gheorghiade, Mihai

Published
2010
Full Text
View/download PDF

26. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial

Author

Packer, Milton Butler, Javed Zannad, Faiez Filippatos, Gerasimos Ferreira, Joao Pedro Pocock, Stuart J. Carson, Peter Anand, Inder Doehner, Wolfram Haass, Markus and Komajda, Michel Miller, Alan Pehrson, Steen Teerlink, John R. Schnaidt, Sven Zeller, Cordula Schnee, Janet M. and Anker, Stefan D. EMPEROR-Preserved Trial Study Grp

Abstract

BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events. METHODS: We randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points. RESULTS: Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% CI, 0.67-0.87]; P40% to

Published
2021

41. Baroreflex sensitivity and heart rate variability in conscious rats with myocardial infarction

Author

Kruger, Carsten, Kalenka, Armin, Haunstetter, Armin, Schweizer, Mark, Maier, Christoph, Ruhle, Ulrike, Ehmke, Heimo, Kubler, Wolfgang, and Haass, Markus

Subjects
Heart attack -- Research, Bradycardia -- Physiological aspects, Biological sciences
Abstract

The relationship between altered baroreflex sensitivity (BRS) and heart rate variability (HRV) and post-myocardial infarction hemodynamic changes were determined through studies of sham-operated conscious rats. Results have shown that BRS was temporarily decreased only with moderate left ventricular dysfunction. Myocardial infarction affected rats have shown temporarily reduced vagal activity with the tonic component unmasked only after autonomic blockade.

Published
1997

46. Significance of psychosocial factors in cardiology: update 2018

Author

Albus, Christian, Waller, Christiane, Fritzsche, Kurt, Gunold, Hilka, Haass, Markus, Hamann, Bettina, Kindermann, Ingrid, Köllner, Volker, Leithäuser, Boris, Marx, Nikolaus, Meesmann, Malte, Michal, Matthias, Ronel, Joram, Scherer, Martin, Schrader, Volker, Schwaab, Bernhard, Weber, Cora Stefanie, Herrmann-Lingen, Christoph, Albus, Christian, Waller, Christiane, Fritzsche, Kurt, Gunold, Hilka, Haass, Markus, Hamann, Bettina, Kindermann, Ingrid, Köllner, Volker, Leithäuser, Boris, Marx, Nikolaus, Meesmann, Malte, Michal, Matthias, Ronel, Joram, Scherer, Martin, Schrader, Volker, Schwaab, Bernhard, Weber, Cora Stefanie, and Herrmann-Lingen, Christoph

Published
2019

49. Role of Na(super+)(sub i) and Ca(super 2+)(sub i) in nicotine-induced norepinephrine release from bovine adrenal chromaffin cells

Author

Gerber, Stefan H., Haunstetter, Armin, Kruger, Carsten, Kaufmann, Alexander, Nobiling, Rainer, and Haass, Markus

Subjects
Noradrenaline -- Physiological aspects, Chromaffin cells -- Observations, Nicotine -- Physiological aspects, Biological sciences
Abstract

The release of H(super 3) norepinephrine, which is nicotine-induced, is accelerated by an increase in Ca+2(sub i) which takes place by the influx of sodium through the nicotinic receptor ionophore. The concentration of intracellular Na+(sub i) and Ca+2(sub i) in bovine adrenal chromaffin cells was determined by sodium-binding benzofuran isophthalate microfluorimetry. The activation of nicotinic receptors causes the release of catecholamines.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results